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Abstract
Ischemic heart disease and stroke are the leading causes of death worldwide. Nonetheless, 
our understanding of the molecular mechanisms regulating cardiac and cerebral isch-
emic injury is very modest and our ability to develop therapies arresting and/or revers-
ing detrimental events that spread from the ischemic core to the surrounding tissue is 
limited. Ischemia occurs when oxygen is unavailable to tissues due to occlusion of an 
artery (myocardial infarction, stroke, and pulmonary embolism), hemorrhage, organ 
transplantation, or hypotension in septic shock. The mitochondrion is a key target of 
ischemia. Alterations in mitochondrial morphology, dynamics, and functions result in 
energy deficits and contribute to the pathogenesis of ischemic injury. Phosphorylations 
of mitochondrial proteins and protein kinases that mediate them are important regu-
lators of mitochondrial functions and tissue ATP levels. Thus, mitochondrial protein 
kinases could serve as targets for therapeutic interventions to mitigate the effects of isch-
emic injury. This will review the mitochondrial proteins regulated by phosphorylation, 
protein kinases mediating these reactions, and their implications in mitochondrial func-
tions in ischemia/reperfusion (I/R)-induced injury.
Keywords: protein kinases, phosphorylation, mitochondria, mitochondrial  
dysfunction, ischemia, reperfusion, injury, ATP, oxidative phosphorylation, electron 
transport chain
1. Introduction
Ischemia (insufficient oxygen and nutrient supply to an organ) can affect all major organs and 
is often encountered in many clinical and nonclinical settings including myocardial infarction, 
stroke, pulmonary embolism, major surgery, tissue trauma and hemorrhage, transplantation 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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and organ storage, or hypotension in septic shock. Functional deficits caused by ischemia 
in major organs result in significant morbidity, disability, and mortality. Mitochondria are 
double-membrane-bound, dynamic organelles present in most eukaryotic cell types. They 
require large amounts of oxygen to generate ~90–95% of the total energy in oxidative phos-
phorylation occurring in a majority of cells [1]. Therefore, mitochondria are the key subcel-
lular targets of ischemia, which undergo pathological changes that trigger cellular and tissue 
damage when oxygen is unavailable. Mitochondria perform several major cellular functions 
including energy and intermediary metabolisms, several biosyntheses, regulation of calcium 
storage, and redox homeostasis [1]. They are also involved in signaling, cell cycle, growth, 
differentiation, and cell death by apoptosis [2].
2. Major mitochondrial targets of ischemia/reperfusion (I/R)
Proteins of the mitochondrial electron transport chain and oxidative phosphorylation are 
among the primary targets of ischemia and oxidative stress during reperfusion [3]. Decreases 
in activities of adenine nucleotide translocase (ANT) and ATP synthase are among the earli-
est events after the onset of cardiac ischemia [4–7]. Inhibition of NADH:ubiquinone dehy-
drogenase (complex I) and reduced cytochrome c content occur early during ischemia [5, 
8], whereas the damage to ubiquinol:cytochrome c oxidoreductase (complex III) and cyto-
chrome oxidase (complex IV) occurs in prolonged ischemia [5, 8]. Reduced activity of com-
plex I is primarily caused by decreases in NADH dehydrogenase activity [5, 9] due to, in 
part, oxidative damage to the flavin mononucleotide (FMN) prosthetic groups, which results 
in electron leakage, superoxide production, and the generation of reactive oxygen species 
(ROS) in ischemic tissues [5, 10]. Ischemia decreases the activity of complex III by inactivating 
the iron-sulfur center, which contributes to electron leakage and superoxide production, and 
exacerbates oxidative stress originating from complex I [11]. The voltage-dependent anion 
channel (VDAC) and proteins of the mitochondrial permeability transition (MPT) pore are 
also targeted by I/R, which disrupts the transport of ions and solutes and the membrane 
potential for ATP synthesis [12, 13].
Mitochondria are dynamic organelles that regularly undergo fission (fragmentation) and 
fusion (formation of a network of mitochondria) [14]. Fission is mediated by the dynamin-
related protein 1 (Drp1) and mitochondrial fission protein 1 (Fis1) [14]. Fusion is regulated 
by the mitofusins (Mfn1 and Mfn2) and the optic atrophy protein 1 (Opa1) [14]. Drp1 
and Opa1 are rapidly activated and translocated to mitochondria after ischemia in major 
organs. This promotes fission, the permeabilization of the mitochondrial outer membrane, 
and the release of proteins that initiate the intrinsic cascade of apoptosis [15, 16]. Inhibition 
of Drp1 inhibits fission and reduces cardiomyocyte death, the size of myocardial infarct, 
and acute kidney injury after ischemia [17]. Mitochondria also regulate the intrinsic cas-
cade of apoptosis, which is activated after the release of mitochondrial proteins. Therefore, 
preservation of mitochondrial integrity and function is crucial for organ protection against 
I/R injury.
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3. Phosphorylation of mitochondrial proteins as a regulatory mechanism 
of energy metabolism during ischemia/reperfusion
Numerous mitochondrial proteins (354 reported to date) are phosphoproteins that collectively 
contain 899 identified and 479 potential novel phosphorylation sites [18, 19]. Consequently, 
phosphorylation of mitochondrial proteins has emerged as an important mechanism involved 
in progressive damage of mitochondria in response to metabolic stresses including I/R and 
the status of these phosphorylations is key to understanding the regulation of mitochondrial 
functions in disease states [18, 19]. A number of protein kinases localize to mitochondria in 
response to I/R [19, 20]. Protein phosphorylations by these kinases produce differential out-
comes in different tissues depending on the phosphorylation site and the kinase involved. The 
key proteins of oxidative phosphorylation, TCA cycle, transport, and the cascade of intrinsic 
apoptosis are regulated by phosphorylation [19–23].
3.1. Phosphorylation of proteins involved in oxidative phosphorylation
The largest group of phosphorylation sites was found among proteins involved in oxidative 
phosphorylation: respiratory complexes, ATP synthase, ANT, and VDAC [18, 19].
4. NADH-ubiquinone oxidoreductase (complex I)
Dysfunction of complex I is the most common disorder of oxidative phosphorylation in 
humans. It is often due to defects of the subunit assembly to form the mature complex 
I. Complex I is a major mitochondrial target of I/R. Its activity decreases as early as 10 min-
utes into cardiac ischemia [24]. Our studies demonstrated that the activity of complex I in 
renal cortical mitochondria is decreased after renal ischemia [25]. Changes in the activity of 
complex I during I/R are also regulated by phosphorylation [4, 26]. Phosphorylations occur 
on several subunits of complex I. The NDUFA10 subunit is phosphorylated on S59 and S95 
[27]. The NDUFS4 and NDUFA10 subunits are phosphorylated by mitochondrial protein 
kinase A (PKA), which stimulates the activity of complex I [27–29]. Phosphorylations of 
subunit ESSS on S20 and subunit MWFE (NDUFA1) on S55 regulate complex I assembly. 
Blocking these phosphorylations inhibits assembly of subunits to form a mature complex I 
and reduces its activity [26, 30]. Tyrosine phosphorylation of the NDUFB10 subunit by Src 
kinases also increases the activity of complex I, possibly by increasing its affinity toward 
NADH or increasing assembly of subunits into the fully active complex I [31, 32]. The 
reduced assembly of subunits leads to decreased levels of complex I [32]. This adapta-
tion shifts fuel utilization from fuels that generate primarily NADH (carbohydrates) to 
fuels generating more FADH
2
 (fatty acids) oxidized by complex II. This shift may occur 
during nutritional restriction or after ischemic injury [32]. Further, complex I is primar-
ily assembled into mitochondrial super-complexes, which increases O
2
 consumption 
and reduces ROS production [33]. Cardiac I/R induces disintegration of mitochondrial 
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super-complexes, which reduces activity of the electron transport chain [34]. Thus, phos-
phorylation controls the formation, stability, and function of complex I and its assembly 
into super-complexes.
5. Succinate-ubiquinone oxidoreductase (complex II)
Complex II is an essential regulator of metabolic reprogramming and respiratory adaptation. 
Mitochondrial Src-type tyrosine kinase Fgr phosphorylates complex II on Y535, Y596, and 
Y604 when activated by ROS generated by I/R [32]. Phosphorylation of Y604 on the flavopro-
tein subunit of succinate dehydrogenase (FpSDH) increases activity of complex II and serves 
as a metabolic adaptation to increased ROS production [32, 34]. Fgr-mediated phosphoryla-
tion also reduces the protein levels of complex I, which alters the mitochondrial preference 
for fuel oxidation from NADH to FADH
2
, which increases the metabolic capacity of mito-
chondria to utilize alternative fuels when complex I is impaired [32]. Blocking phosphoryla-
tion of FpSDH on Y604 abolishes the capacity of mitochondria to adapt their metabolism 
after hypoxia/reoxygenation [32]. Mitochondrial phosphatases dephosphorylate Y604 and 
reverse this metabolic adaptation [32, 34]. In contrast, phosphorylation of FpSDH in cancer 
cells undergoing hypoxia decreases and dephosphorylation of FpSDH increases SDH activ-
ity [35]. Our data show that the activity of complex II in injured renal proximal tubular cells 
(RPTC) and in the ischemic kidney cortex is unchanged, whereas the activity of complex I is 
decreased [25, 36]. Supplementing the RPTC with succinate (complex II substrate) ameliorates 
mitochondrial dysfunction, ATP deficits, oxidative stress, and cell death after injury associ-
ated with the generation of ROS and oxidative stress [36].
6. Ubiquinol-cytochrome c oxidoreductase (complex III)
Phosphorylation has been implicated in the regulation of the Rieske iron-sulfur protein 
of complex III, which is a major target of ischemia and the decreases in its activity lead to 
increased superoxide production [37]. Several phosphorylation sites have been identified on 
the subunits of complex III. The tyrosines on the core subunit 1 of complex III are phosphory-
lated by the Src kinase family, but the functional consequence of this phosphorylation is not 
yet known [38]. The role of phosphorylation of Rieske iron-sulfur protein is not clear and it 
was suggested that it regulates the MPTP opening [37].
7. Cytochrome oxidase (complex IV)
To date, 14 phosphorylation sites have been mapped on complex IV [39]. Tyrosine phos-
phorylation of the specific subunits of complex IV can lead to both inhibition and activa-
tion of complex IV activity [39, 40]. Bender and Kadenbach have shown phosphorylation 
of complex IV subunits I, II/III, and Vb in vitro [41]. cAMP-dependent phosphorylation of 
Y304 on the catalytic subunit I inhibits, whereas tyrosine phosphorylation of subunit II by 
Mitochondrial Diseases186
c-Src kinase activates complex IV [41, 42]. The latter event is required for the normal func-
tion of cells, which are dependent on the efficient production of ATP to maintain their func-
tions [42]. Interestingly, phosphorylation of the same subunit by the receptor tyrosine kinase 
ERBb2 decreases the activity of complex IV and mitochondrial respiration [43, 44]. Complex 
IV activity is inhibited in a time-dependent manner after myocardial ischemia, which stimu-
lates multiple phosphorylations of complex IV: (1) subunit I on S115 and S116, (2) subunit 
IVi1 on T52, and (3) subunit Vb on S40 in the heart [38, 45]. These inhibitory phosphoryla-
tions are mediated by PKA and inhibition of PKA reduces I/R injury to the myocardial tissue 
[45]. Phosphorylation of subunit IV-1 on S58 by PKA increases the activity of complex IV by 
preventing allosteric inhibition of complex IV by ATP [46]. It was proposed that phosphoryla-
tion of S58 switches mitochondrial metabolism from energy utilization to energy storage in 
pathological conditions including I/R-induced injury [46].
8. Cytochrome c
Phosphorylations of serine, threonine, and 2 tyrosine residues have been mapped on cyto-
chrome c [39, 47]. Phosphorylation of T28 results in a partial inhibition of the electron trans-
port chain and respiration [48]. It was suggested that the other phosphorylations regulate the 
mobility of cytochrome c between complexes, its binding to cardiolipin, and the interaction 
with Apaf-1 during apoptosis [47].





Multiple and differential phosphorylations of ATP synthase have been reported in different 
organisms and tissues. Tyrosine phosphorylations of the ε-subunit (in the F
o
 domain) and 
the α- and δ-subunits of the F
1





-ATPase in mammalian brain are phosphorylated on S76 and Y32 [51]. The cat-
alytic β-subunit is extensively phosphorylated on S106, T107, T262/S263, T312, and T368 in 
mammalian cardiomyocytes, whereas in yeast, the β-subunit is phosphorylated on T58, S213, 
T262, and T318 [51]. These phosphorylations affect assembly of the F
1
 domain and reduce 
ATP synthase activity [51]. They occur in cardiac preconditioning, which offers protection 





downregulates its levels in vivo [6, 51]. We have shown serine phosphorylations on the α 
and/or β- and γ-subunits of ATP synthase in RPTC [52]. These phosphorylations are PKC-α-




-ATPase activity in injured renal 
cells [52]. Phosphoproteomics demonstrated phosphorylation of S146 on the γ-subunit [52]. 
Phosphorylation of the γ-subunit is associated with the formation of ATP synthase dimers [52].
10. Adenine nucleotide translocase (ANT)
ANT, an antiporter embedded in the inner mitochondrial membrane that facilitates the 
exchange of ADP and ATP, is one of the most abundant mitochondrial proteins and a primary 
Protein Kinases and Regulation of Mitochondrial Function in Ischemia/Reperfusion Injury
http://dx.doi.org/10.5772/intechopen.71094
187
target of ischemia [5, 53]. The four human isoforms, ANT1, 2, 3, and 4, are phosphorylated 
on tyrosines [49]. Phosphorylation of ANT on Y194 and Y190 alters the activity of ADP/ATP 
translocase and the transport of both nucleotides in the brain [49]. Phosphorylation of ANT1 
at Y194 in cardiac tissue is diminished by I/R but maintained by pre- and post-conditioning, 
which suggests that this phosphorylation plays a protective role against ischemia in the heart 
and could improve tolerance against injury [54]. Although this phosphorylation improves 
respiration and mitochondrial function, it is not known whether phosphorylation of Y194 is 
sufficient for protection of cardiomyocytes from I/R-induced injury [54]. A binding of phos-
phorylated (inactive) glycogen synthase kinase-3β (GSK-3β) to ANT was also shown, but it is 
unclear whether GSK-3β directly phosphorylates ANT [55].
11. Voltage-dependent anion channel (VDAC)
VDAC, a channel protein localized to the outer mitochondrial membrane, conducts a variety 
of small metabolites (NAD+/NADH, ADP, and ATP) and ions across the outer membrane and 
is a key regulator of energy metabolism [56]. VDAC forms a complex with ANT, which facili-
tates influx of ADP into mitochondria and the efflux of ATP to the cytoplasm [56–58]. VDAC1 
closure leads to hyperpolarization of mitochondria, disruption of ADP/ATP exchange, 
decrease in ATP synthesis, and metabolic dysfunction, and rupture of mitochondria [56–58]. 
The four known VDAC isoforms present in the outer mitochondrial membrane are phos-
phorylated on multiple serines and threonines [21, 22]. A total of 19 distinct phosphorylations 
were identified in VDAC isoforms [21, 65]. These phosphorylations are mediated by different 
kinases including PKA, PKC, tyrosine kinase, hexokinase, GSK-3β, Akt, JNK3, and p38 [59]. 
The phosphorylation of neuronal and hepatic VDAC1 by PKA and ischemia-activated GSK-3β 
and JNK induces its closure, disrupts formation of the complex with ANT, and decreases ATP 
synthesis [59]. In contrast, phosphorylation of cardiac VDAC1 by protein kinase C-ε (PKC-ε) 
promotes formation of the VDAC-ANT complex, prevents the opening of MPTP, and protects 
mitochondrial integrity after I/R injury [60]. Phosphorylation of VDAC1 by never-in-mitosis 
A related kinase 1 (Nek1) on S193 closes the channel in RPTC, blocks release of cytochrome c, 
and prevents cell death by apoptosis [61]
11.1. Phosphorylation of enzymes of the tricarboxylic acid cycle (TCA)
Phosphoproteomic analyses revealed that most enzymes of the TCA cycle are phosphory-
lated/dephosphorylated [62]. These include aconitase, isocitrate and oxo-ketoglutarate dehy-
drogenases, succinyl-coenzyme A synthetase, succinate dehydrogenase, fumarate hydratase, 
and mitochondrial malate dehydrogenase [62, 63]. Although the functional role of these phos-
phorylations and the protein kinases that mediate them are not yet known, data suggest that 
phosphorylation regulates the activity of these enzymes.
11.2. Pyruvate dehydrogenase complex (PDC)
PDC is composed of multiple copies of three distinct enzymes: (1) pyruvate dehydrogenase 
(E1), dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3), which form 
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a large complex. PDC is the rate-limiting enzyme in the oxidative metabolism of all carbohy-
drates and its activity is tightly regulated by multiple mechanisms including phosphoryla-
tion. Phosphorylation of the PDC by the pyruvate dehydrogenase kinase (PDK) inactivates 
the complex [64]. The α-subunit of the E1 is phosphorylated at multiple sites, but the most 
known are phosphorylations of three distinct serines [64]. Although phosphorylation at any 
of these serines is sufficient to inhibit the activity of PDC, the S293 residue has the highest 
affinity for phosphate, and phosphorylation of this serine has the greatest impact on the inhi-
bition of activity of PDC [64, 65]. I/R-induced injury in cardiac tissue is associated with a 4–5-
fold decrease in the phosphorylation of S293, which results in the activation of PDC [64]. PDC 
activation protects against ischemic injury and improves cardiac efficiency and contractile 
capacity in the postischemic heart [65].
11.3. Proteins involved in mitochondrial dynamics
Mitochondrial morphology is dynamically changed by the balance between fusion and fission 
(fragmentation). Phosphorylations of GTPases, Drp1, Mfn1/2, and Opa1 regulate mitochon-
drial fission and fusion [66]. Phosphorylation of fission-inducing Drp1 on S616 and S637 can be 
mediated by cyclin-dependent kinase (cdk)-1, cdk-5, PKA, PKC-δ, and extracellular signal reg-
ulated kinase-2 (ERK-2) [66–71]. Phosphorylation of Drp1 at S616 by cdk-1, PKC-δ, and ERK-2 
promotes Drp1 translocation to mitochondria and fission whereas phosphorylation of S637 by 
PKA inhibits Drp1 and mitochondrial fission [67–71]. We have demonstrated that activation of 
PKC-ε induces the translocation of Drp1 to mitochondria, mitochondrial fission and apoptosis 
in non-injured RPTC [72]. Drp1-dependent mitochondrial fission is associated with mitochon-
drial outer membrane permeabilization and apoptosis, whereas elongation of the mitochon-
dria through fusion promotes ATP synthesis and prevents mitochondrial autophagy. When 
phosphorylated by ERK, Mfn1 has decreased ability to oligomerize and tether mitochondria, 
which inhibits their fusion, recruitment of Bak to the mitochondria, and apoptosis [73]. Mfn2 is 
phosphorylated on T111 and S442 by PTEN-induced putative kinase protein 1 (PINK1), which 
recruits the protein Parkin to depolarized mitochondria and eliminates them by mitophagy 
[74]. Disruption in the balance between fission and fusion occurs in pathological conditions 
including I/R, which increases phosphorylation of Drp1, its translocation to mitochondria, and 
mitochondrial fission in the heart and brain [75]. Inhibition of Drp1 protects the heart and brain 
against ischemia and has been proposed as a therapeutic target following cardiac arrest [76].
11.4. Proteins of the intrinsic apoptotic cascade
Mitochondrial proteins involved in the intrinsic apoptosis include Bcl-2 family members, AIF, 
Smac/DIABLO, cytochrome c, and Omi/Htra2. With an exception of one, all are regulated by 
phosphorylation [20]. Phosphorylation of Bcl-2 at S70 is required to prevent permeabilization 
of the mitochondrial outer membrane and for Bcl-2’s anti-apoptotic activity [77]. Several pro-
tein kinases serve as Bcl-2 kinases to inhibit (JNK, p38, and GSK-3) or activate (Akt, PKA, and 
PKC-α) Bcl-2 [77]. Cardiac and neuronal tissues are protected against I/R when Bcl-2 is active 
[78–80]. Ischemia-induced acute kidney injury upregulates Bcl-2 and Bcl-XL in the distal and 
Bax in the proximal tubules [80]. Pro-apoptotic Bax, Bak, Bad, and Bid are phosphorylated on 
serines and tyrosines, which controls their insertion into the outer mitochondrial membrane 
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and formation of pores that mediate the release of pro-apoptotic AIF, Smac, and cytochrome c 
from the mitochondria [81]. Smac is phosphorylated by JNK3, which decreases its pro-apop-
totic actions [81]. Phosphorylation of Y97 and Y48 on cytochrome c regulates its capacity to 
form the apoptosome and activate caspase-9 [81]. Thus, phosphorylation of specific amino 
acids on a mitochondrial protein determines the fate of mitochondria by protecting their 
integrity and functions or inducing MPT and apoptosis.
12. Role of protein kinases in regulating mitochondrial functions in 
ischemia/reperfusion
Ischemia rapidly changes activities of different protein kinases including the calcium/calmod-
ulin-dependent protein kinase II (CaMK-II), PKA, protein kinase B (PKB/Akt), PKC, Raf-1, 
ERK1/2, c-jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38 MAPK), 
GSK3-β, PINK1, and tyrosine kinases, which suggests their involvement in I/R injury.
12.1. Protein kinases regulating large dehydrogenase complexes
A specific family of protein kinases is exclusively present in the mitochondrial matrix of 
eukaryotic cells. These kinases have different sequences from the cytosolic protein kinases 
and they phosphorylate and inactivate large enzymatic complexes in the mitochondrial 
matrix, the branched-chain α-ketoacid dehydrogenase complex and pyruvate dehydrogenase 
complex, PDC. Perturbations in PDC activity result in energy deficits, neuronal dysfunction, 
and brain injury, such as those observed in stroke. Phosphorylation of the E1 α-subunit of 
PDC by PDK isozymes inhibits, whereas dephosphorylation increases PDC activity [82]. 
Cardiac and cerebral ischemia has no effect on the activity of PDC; however, reperfusion 
results in a fast decline in PDC activity in the brain [83]. Increased expression of PDK2 fol-
lowing traumatic brain injury may maintain E1 in the hyperphosphorylated (inactive) state, 
which impairs glucose oxidation after stroke and traumatic brain injuries [83]. Further, reper-
fusion-induced oxidative stress activates PKC-δ, which translocates to mitochondria and acti-
vates PDK2 leading to inhibition of E1 activity [84]. The inhibition of PDK during reperfusion 
restores PDC activity and decreases brain injury, demonstrating that phosphorylation by 
PDK2 mediates inhibition of PDC activity [85]. Infusion of the specific peptide inhibitor of 
PKC-δ, Tat-δV1-1, prevents the translocation of PKC-δ to mitochondria and maintains PDC 
activity [84]. Isozymes of PDK are considered attractive targets for therapies to improve PDC 
activity to diminish the detrimental effects of I/R in tissues that depend on metabolism of 
glucose, such as neuronal and cardiac tissues.
12.2. Serine/threonine kinases in regulation of mitochondrial functions in ischemia/
reperfusion
12.2.1. Protein kinase A
PKA is activated by a signaling pathway originating from G-protein receptors, which pro-
duces cAMP. The association of PKA with mammalian mitochondria was documented four 
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decades ago [86]. Mitochondrial PKA is present in the outer and inner mitochondrial mem-
branes as well as in the mitochondrial matrix [28, 87]. Several mitochondrial substrates of 
PKA with distinct tissue-specific responses have been identified. During myocardial I/R, PKA 
is activated by increased levels of ROS and translocates to mitochondria [88]. The increase in 
activity of mitochondrial PKA is independent of mitochondrial levels of cAMP and is due to 
increased sequestration of the catalytic α-subunit in the mitochondrial matrix [88]. The pres-
ence of the catalytic α-subunit of PKA results in phosphorylation of subunits I (on S115 and 
S116), IVi1 (on T52), and Vb (on S40) of complex IV, followed by their degradation and the 
loss of activity [38, 40, 88]. Because the identified phosphorylation sites on complex IV are 
not within PKA consensus sites, it was proposed that PKA activation plays an indirect role in 
the loss of complex IV activity during myocardial ischemia [39]. These changes are sufficient 
to disrupt the function of mitochondrial respirasome and increase production of ROS [88]. 
PKA-mediated phosphorylation regulates ischemia-induced dysfunction of complex IV [38, 
45, 88]. Ca2+ influx activated by PKA in cardiomyocytes induces mitochondrial permeability 
transition, which stimulates caspase-9 and apoptosis [89]. Inhibition of PKA prevents the loss 
of activity of complex IV during cardiac I/R, promotes postischemic cardiac contractile recov-
ery, and decreases the infarct size in the ischemic heart [38, 45, 90]. Thus, PKA inhibitors could 
serve as candidates for cardioprotective agents [87, 89]. PKA also phosphorylates NDUFS4 
and NDUFA10 subunits of complex I and this phosphorylation stimulates the activity of com-
plex I and complex I-driven respiration [28, 29, 91]. Finally, Hsp20, which localizes to mito-
chondria and is expressed at high levels in cardiac, skeletal, and vascular smooth muscle, is 
regulated by the β-adrenergic/PKA signaling pathway [92]. PKA-mediated phosphorylation 
of Hsp20 on S16 increases in ischaemic myocardium and is cardioprotective [92].
In contrast, the activation of PKA during liver IR is cAMP-dependent and plays a protective 
role against liver injury [93]. The cAMP that activates mitochondrial PKA does not origi-
nate from membrane-bound adenylyl cyclase activated by the Gα protein, but is produced 
inside mitochondria by the carbon dioxide/bicarbonate-regulated soluble adenylyl cyclase in 
response to metabolically generated carbon dioxide [93]. Mitochondrial PKA regulates mito-
chondrial biogenesis, normalizes ROS production, and activates complex IV [46]. Inhibition 
of PKA exacerbates hepatocellular damage, whereas increasing cAMP levels to activate PKA 
protects the ischemic liver from injury [93]. PKA activation diminishes neutrophil and mac-
rophage infiltration into ischemic liver tissue, reduces production of tumor necrosis factor 
α, interleukin (IL)-6, and IL-12 by macrophages, increases IL-10 expression, and prevents 
hepatocyte death [93]. Thus, PKA activation reduces the inflammatory response associated 
with reperfusion after liver ischemia. Because ischemia is an inherent component of liver 
transplantation, activation of PKA was proposed as a rationale for novel therapies to combat 
I/R injury and protect transplants [94]. However, increased cAMP levels in the liver in vivo 
inhibit complex IV due to phosphorylation of Y304 [41]. Because PKA is not a tyrosine kinase, 
it was proposed that PKA activates a downstream tyrosine kinase, which phosphorylates and 
inactivates complex IV [41]. Therefore, attempts aimed at activating PKA to protect the liver 
against ischemia should be treated with great caution.
PKA dysregulation has been implicated in several neurodegenerative disorders. PKA-
dependent pathways in different regions of the brain play a role in pathogenesis and cogni-
tive decline in Alzheimer and Parkinson’s diseases [94]. The acute phase of cerebral ischemia 
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is accompanied by decreases in affinity of PKA for cAMP and PKA activity [94]. In contrast, 
the peri-ischemic and less-injured areas exhibit increased PKA-mediated phosphorylation 
compared to the ischemic core, which suggests that active PKA is associated with the survival 
of neuronal tissue [94]. Derangement of cAMP-dependent signal transduction is associated 
with ischemic neuronal damage and activation of the PKA is important for neuronal survival 
in acute cerebral ischemia [94]. Phosphorylation of Bad at S155 by mitochondria-anchored 
PKA leads to cytosolic sequestration of Bad and blocks its mitochondrial translocation, the 
release of cytochrome c, and neuronal apoptosis [77]. Also, PKA-mediated phosphoryla-
tion of Drp1 at S637 blocks its translocation to mitochondria and their fission and promotes 
mitochondrial fusion. In hippocampal neurons, expression of a constitutively active catalytic 
subunit of PKA targeted to the mitochondrion promotes the fusion of mitochondria into net-
works [95]. Finally, PKA suppresses autophagy and mitochondrial degradation in neurons by 
phosphorylating and inhibiting the microtubule-associated protein 1A/1B-light chain 3 (LC3) 
and increases neurite outgrowth [94, 96].
12.2.2. Protein kinase B (PKB/Akt)
Akt can localize to the mitochondrial matrix and the inner and outer membranes of cardiac, 
neuronal, and kidney cells [97, 98]. Protein levels of mitochondrial Akt are regulated by a 
variety of extracellular signals and stresses, which induce rapid translocation of active (phos-
phorylated) Akt to the mitochondria [97, 98]. Mitochondrial localization of Akt is associated 
with cardioprotection against ischemic injury and renoprotective actions against chemical 
toxicity [97–100]. The cardioprotective effect of mitochondrial Akt is attributed to its action 
on mitoK(ATP) channels and to decreasing apoptosis [99]. Akt phosphorylates pro-apoptotic 
Bad on S136 and Bax on S184, and prevents MPT in neuronal cells [101]. Phosphorylated Bad 
associates with 14-3-3 proteins in the cytosol and cannot form complexes with mitochon-
drial Bcl-2/Bcl-XL to induce permeabilization of the mitochondrial outer membrane and MPT 
[101]. Bax phosphorylation by Akt promotes dimerization of Bax with Bcl-XL or Mcl-1 pro-
teins, which sequesters Bax away from mitochondria and prevents their permeabilization and 
apoptosis [101]. Akt prevents the MPT in cardiomyocytes by phosphorylating hexokinase II, 
stabilizing it in the outer mitochondrial membrane, and promoting its binding to VDAC [102]. 
Inhibition of Akt or targeted disruption of the association of hexokinase II with mitochondria 
abolishes cardioprotection [102].
We have identified mitochondria as a subcellular target of protective actions of Akt against 
necrosis in injured RPTC [98]. Mitochondrial levels of active Akt decrease in injured RPTC 
and this is associated with mitochondrial dysfunction [98, 100]. Selective activation of Akt 
increases the levels of Akt in mitochondria, improves state 3 respiration, activities of com-




-ATPase (ATP synthase), and the mitochondrial membrane poten-
tial (ΔΨ
m
), increases ATP production, and reduces ATP deficits [100]. Selective inhibition of 
Akt exacerbates mitochondrial dysfunction, energy deficits, and necrosis in injured RPTC 
[100]. These results are consistent with a report that Akt phosphorylates the β-subunit of ATP 
synthase and improves its activity and increases ATP production to prevent energy deficits 
in injured cells [97]. Also, active Akt increases activity of PDC and oxidative metabolism of 
carbohydrates by inhibiting phosphorylation of PDC by GSK-3β [103]. Thus, signals from cell 
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membrane receptors or those generated by metabolic stress have a rapid effect on Akt activa-
tion status in mitochondria. Akt could serve as a therapeutic target promoting mitochondrial 
functions in ischemic organs. However, the application is complicated by the fact that Akt 
promotes tumor formation by blocking apoptosis.
12.2.3. Protein kinase C
PKC plays a key role in mediating I/R injury in the brain, heart, and kidneys; however, eluci-
dation of this role is complicated due to the presence of 11 distinct PKC isozymes, which have 
unique tissue and cellular localizations and often play quite opposite roles in ischemic injury 
even within the same organ. Alterations in PKC activity or subcellular localization during 
ischemia occur in the brain, heart, liver, and kidney [25, 104–106]. Major isozymes of PKC (α, 
β, γ, δ, ε) translocate to mitochondria in response to ischemia and/or reperfusion and oxida-
tive stress, and have been implicated in regulating mitochondrial functions in ischemic and 
postischemic tissues [104]. The classical PKC isozymes (α, β, γ) are dependent on Ca2+ and 
1,2-diacylglycerol, and ischemia increases the levels of both activators through the stimulation 
of phospholipase C. PKC-α activation has been implicated in ischemia-induced heart failure 
and cerebral barrier breakdown after ischemic stroke [107, 108]. PKC-α inhibition or deletion 
protects the heart from decompensation and cardiomyopathy and attenuates cerebral barrier 
breakdown after ischemia [107, 108]. In contrast, PKC-α translocation to mitochondria is pro-
tective against mitochondrial dysfunction, ATP deficits, and cell death caused by ischemia, 





is a target of PKC-α, which associates with the α-, β-, and γ-subunits of the F
1
 domain of ATP 
synthase [52]. Injury or inactive PKC-α disrupt, whereas active PKC-α promotes this asso-
ciation and increases the levels of α-, β-, and γ-subunits in injured RPTC [52]. Active PKC-α 




-ATPase activity after injury [52]. 
PKC-α also reduces apoptosis by phosphorylating mitochondrial Bcl-2 on S70 [77, 110]. Thus, 
activation of PKC-α exerts differential effects in different types of cells and tissues.
PKC-γ is expressed exclusively in neurons of the brain and spinal cord and is activated rap-
idly during ischemia and inhibited during reperfusion [111–114]. PKC-γ plays a detrimental 
role in the early stages of ischemia mediating events leading to cell death. PKC-γ knockouts 
show smaller infarct areas after cerebral ischemia [112]. Also, PKC-γ may directly (or through 
the activation of a Src tyrosine kinase) phosphorylate NMDA receptors, stimulate their func-
tion, and increase the concentration of intracellular Ca2+, which results in mitochondrial dys-
function, ATP deficits, increased ROS formation, and neuronal death [112]. However, after 
reperfusion, PKC-γ may mediate protection against cell death [112]. Thus, the same PKC 
isozyme may play opposing roles at different stages of ischemic injury.
PKC-δ is rapidly activated by signaling initiated by reperfusion. PKC-δ plays a detrimen-
tal role in ischemic stroke injury and mediates oxidative stress, cell death, and inflamma-
tion associated with reperfusion [111, 112]. Selective inhibition or deletion of PKC-δ reduces 
infarct size and ischemic brain injury caused by middle cerebral artery occlusion, specifi-
cally, reperfusion-induced death of parenchymal cells [115, 116]. PKC-δ inhibition activates 
PKB/Akt, inhibits translocation of Bad to mitochondria, and decreases apoptosis [112]. PKC-δ 
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mediates neutrophil infiltration, which is responsible for the detrimental effects of PKC-δ 
during reperfusion [112]. Similarly, reperfusion after cardiac ischemia activates PKC-δ, which 
translocates to mitochondria and reduces state 3 respiration, TCA cycle, and ATP produc-
tion, increases generation of mitochondrial ROS, and induces release of cytochrome c and cell 
death [84, 113, 115, 116]. Selective inhibition of PKC-δ translocation to mitochondria blocks 
these changes and protects the heart from ischemic injury [117]. PKC-δ is also activated by 
oxidative stress in the kidney, exacerbates RPTC and kidney injury by activating Bax, induc-
ing cytochrome c release and apoptosis, and blocking autophagy. PKC-δ inhibition protects 
kidneys from injury by upregulating autophagy [118].
PKC-ε, another novel isozyme, is activated and translocates to mitochondria during I/R. These 
events have been implicated in the cardio- and neuro-protection against ischemic injury and 
in the reduction of myocardial infarct [119, 120]. PKC-ε activation is a pivotal signaling event 
in the cardioprotective mechanisms of ischemic preconditioning, and it is thought that this 
protection is mediated through mitochondrial and transport mechanisms [120]. Conversely, 
inhibition of PKC-ε eliminates the cardioprotection [120]. Several substrates of PKC-ε are 
present in cardiac mitochondria. Active PKC-ε induces opening of the mitoK(ATP) channels, 
maintains ATP production, and reduces ROS production [120]. Specifically, PKC-ε regulates 
interactions between conexin43 and the mitoK(ATP) subunit, which leads to mitoK(ATP) 
opening when ATP levels decrease, resulting in cardioprotection [121]. Active PKC-ε also 
increases phosphorylation of subunit IV and the activity of complex IV [122]. Thus, the 
PKC-ε-mediated resistance to cardiac ischemia may also be due to increased activity of the 
electron transport chain and a greater ΔΨ
m
 for ATP synthesis. Also, PKC-ε phosphorylates 
VDAC1 on T51, which modifies its gating and interaction with proteins of the MPT pore to 
inhibit its opening and maintain ΔΨ
m
 and ATP synthesis [60]. These data support protective 
and prosurvival actions of mitochondrial PKC-ε in cardiac I/R. In contrast, translocation of 
the active PKC-ε to mitochondria in RPTC results in mitochondrial dysfunction, decreases in 
ATP levels, mitochondrial fission, and RPTC death [25, 72]. Active PKC-ε produces the clas-
sical hallmarks of mitochondrial dysfunction in RPTC: decreases in state 3 respiration and 
activity of complex I, increases in ΔΨ
m
, ROS production, and mitochondrial fission [25, 72]. 
Inhibition of PKC-ε protects against mitochondrial dysfunction induced by hypoxia and oxi-
dative stress [72]. Deletion of PKC-ε in vivo ameliorates I/R-induced decreases in respiration 
and activities of complexes I, III, and IV, and reduces oxidant production and morphological 
damage in ischemic kidneys [25]. Deletion of PKC-ε reduces the inflammatory response and 
apoptosis, and promotes renal function and survival after I/R-induced acute kidney injury in 
mice [25, 123]. Thus, in contrast to the cardio- and neuroprotective effects of PKC-ε, activa-
tion of this PKC isozyme in the renal cortex is detrimental to mitochondria, cell viability, and 
kidney functions [25, 123].
12.2.4. Mitogen-activated protein kinases (MAPK)
ERK1/2 localize to the mitochondria of cardiac, brain, and renal epithelial cells. Brain and car-
diac ischemia activates ERK1/2, which form signaling modules with PKC-ε and translocate 
to mitochondria [124–126]. ERK1/2–PKC-ε modules play a role in the phosphorylation and 
inactivation of Bad, which blocks the intrinsic pathway of apoptosis [126]. Furthermore, active 
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ERK1/2 associates with the outer mitochondrial membrane and protects against MPTP open-
ing and mitochondrial depolarization [127]. These events are thought to contribute to the car-
dioprotective effects of ERK1/2 activation against I/R injury. In contrast, ERK1/2 activation is 
detrimental to mitochondria and cell viability in RPTC [128]. We have shown that ERK1/2 acti-
vation and translocation to mitochondria in response to oxidant injury mediates mitochondrial 
dysfunction and cell death in RPTC [128]. ERK1/2 activation mediates decreases in state 3 res-
piration, activities of aconitase of the TCA cycle and complex I of the electron transport chain, 
and ATP production in injured RPTC [128]. ERK1/2 inhibition restores respiration, complex I 
activity, ΔΨ
m
 and ATP production, and decreases RPTC death [128]. Recently, it was shown 
that ERK1/2 downregulates mitochondrial function through the EGFR/ERK1/2/FOXO3a/1/
PGC-1α pathway by phosphorylating the upstream regulators of PGC-1α and decreasing 
mitochondrial biogenesis [129]. Similarly, ERK1/2 activation mediates inflammatory changes, 
infiltration by neutrophils, apoptosis, and severe injury after ischemia in the lung [130].
JNK and p38 MAPK are activated and localize in cardiac mitochondria after ischemia or oxi-
dant exposure and mediate mitochondria-initiated apoptosis [131]. p38 MAPK inhibition 
attenuates the loss of ΔΨ
m
, mitochondrial swelling, and ultrastructural changes, reduces car-
diomyocyte apoptosis and infarct size, and improves left ventricular function after ischemia 
[131, 132]. Inhibition of p38 MAPK also decreases phosphorylation of p53 and Bax expression 
and reduces cytochrome c release from mitochondria and the levels of active caspase 3 [132]. 
These data suggests that active p38 MAPK mediates apoptosis.
12.2.5. Glycogen synthase kinase
GSK3β activated by cardiac I/R docks to mitochondria, phosphorylates VDAC1, and leads 
to phosphorylation of ANT and cyclophilin D, and MPTP opening [55, 133]. This suggests 
that GSK3β plays a role in mitochondria-mediated apoptosis in cardiac tissue. GSK3β also 
regulates mitochondrial oxidative metabolism by phosphorylating and inhibiting PDC [65]. 
Activation enhances whereas inhibition of GSK3β activates mTOR pathway, inhibits mTOR-
dependent autophagy, and reduces myocardial I/R injury [134]. Inhibition of GSK-3β also 
attenuates brain infarct volume after cerebral I/R-induced injury [135].
12.2.6. PTEN-induced kinase 1
The mitochondrial serine-threonine protein kinase, PTEN (phosphatase and tensin homolog 
on chromosome 10)-induced kinase 1 (PINK1) localizes to both mitochondrial membranes 
and regulates mitochondrial function and dynamics [136]. PINK1 phosphorylates mitofusin 
MFN2, a mitochondrial receptor for Parkin (a protein related to Parkinson’s disease) [136]. 
PINK1 regulates mitochondrial dynamics in ischemic stroke and prevents damage to neurons 
by reducing mitochondrial translocation of Drp1 and fission, and preventing the collapse 
of ΔΨ
m
 and ATP synthesis [137, 138]. Deletion of PINK1 causes defects in the turnover of 
proteins of the electron transport chain, impairs mitochondrial respiration and activity of 
complex I in cardiomyocytes, induces MPTP opening, decreases production of ATP, exacer-
bates oxidative stress, and increases the size of ischemic myocardial infarct, which suggests 
increased susceptibility to I/R injury in PINK1-deficient hearts [139]. Overexpressing PINK1 
Protein Kinases and Regulation of Mitochondrial Function in Ischemia/Reperfusion Injury
http://dx.doi.org/10.5772/intechopen.71094
195
reduces these changes [139]. Thus, this study suggests mitochondrial PINK1 as a target for 
cardioprotection against ischemia in the heart.
12.3. Tyrosine kinases and regulation of mitochondrial functions in ischemia/reperfusion
Tyrosine phosphorylation is a crucial mechanism for regulating mitochondrial functions [19, 
42]. Tyrosine kinases of the Src family (Lyn, Lck, c-Src, Fyn, and Fgr) localize to mitochon-
dria by binding to specific anchoring proteins present in mitochondria [19, 42]. The primary 
known role of tyrosine phosphorylation is the regulation of the respiratory chain by c-Src [19]. 
Phosphorylations of NDUFB10 subunit of complex I at Y193, succinate dehydrogenase of com-
plex II at Y215, and subunit II of complex IV on unknown tyrosine by Src increase activities of 
complexes I, II, and IV [19, 31, 42]. Targeting of c-Src to mitochondria enhances ΔΨ
m
 and oxi-
dative phosphorylation in a c-Src-dependent manner [19]. Src and Lck phosphorylate ANT1 
at Y194 and reduce ischemic injury in preconditioned cardiac cells [54]. Mitochondrial Fgr 
kinase phosphorylates complex II, which increases complex II activity and regulates NADH/
FADH
2
 balance in mitochondria [32]. Epidermal growth factor receptor (EGFR) translocates to 
mitochondria when phosphorylated on Y845 by Src [43]. EFR interacts with and phosphory-
lates subunit II of complex IV thereby decreasing its activity and cellular ATP levels [19, 140].
In conclusions, translocation of protein kinases to mitochondria regulates mitochondrial 
functions in various disease states including ischemia and reperfusion in major organs such 
as the brain, heart, and kidneys. These findings suggest that these protein kinases can serve as 
potential effective therapeutic targets to maintain mitochondrial integrity and functions and 
prevent or reduce organ damage in these disease states.
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